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Abstract
Background:  Human mastocytosis is a heterogenous disorder which is linked to a gain-of-
function mutation in the kinase domain of the receptor tyrosine kinase Kit. This D816V mutation
leads to constitutive activation and phosphorylation of Kit with proliferative disorders of mast cells
in the peripheral blood, skin, and spleen. Most PCR applications used so far are labour-intensive
and are not adopted to daily routine in pathological laboratories. The method has to be robust and
working on such different materials like archival formalin-fixed, paraffin-embedded tissue (FFPE)
and blood samples. Such a method is introduced in this publication.
Methods: The Kit point mutation Asp 816 to Val is heterozygous which means a problem in
detection by PCR because the wild-type allele is also amplified and the number of cells which bear
the point mutation is in most of the cases low. Most PCR protocols use probes to block the wild-
type allele during amplification with more or less satisfying result. This is why point-mutated
forward primers were designed and tested for efficiency in amplification of the mutated allele.
Results: One primer combination (A) fits the most for the introduced PCR assay. It was able just
to amplify the mutated allele with high specificity from different patient's materials (FFPE or blood)
of varying quality and quantity. Moreover, the sensitivity for this assay was convincing because 10
ng of DNA which bears the point mutation could be detected in a total volume of 200 ng of DNA.
Conclusion: The PCR assay is able to deal with different materials (blood and FFPE) this means
quality and quantity of DNA and can be used for high-througput screening because of its
robustness. Moreover, the method is easy-to-use, not labour-intensive, and easy to realise in a
standard laboratory.
Background
1,000 to 8,000 incidences of human mastocytosis are
reported every year in the US [1]. Human mastocytosis is
characterised by accumulation of mast cells in different
organs. It is a heterogenous group of disorders which can
be divided into the categories cutaneous mastocytosis
(CM) and systemic mastocytosis (SM) which is com-
monly seen in adults by histological lesions in the bone
marrow and other non-cutaneous organs [2,3]. SM can be
further divided into the categories indolent systemic mas-
tocytosis (ISM), SM with an associated clonal hemato-
logic non-mast cell lineage disease (AHNMD), aggressive
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sytemic mastocytosis (ASM), and mast cell leukemia
(MCL). ISM is the most common form which involves
skin, bone marrow, and GI tract with good prognosis for
the patient. First relations between mastocytosis and acti-
vating mutations in the receptor tyrosine kinase Kit came
from the human mast cell line HMC-1 [4]. A gain-of-func-
tion mutation in the kinase domain of Kit (D816V) leads
to constitutive tyrosine kinase activation and phosphor-
ylation of Kit. The consequence is a ligand-independent
cell proliferation. It has been shown that this point muta-
tion causes mastocytosis of peripheral blood lymphocytes
and skin and spleen mast cells [5,6].
There is a strong need for a reliable and sensitive method
for detection of the Kit point mutation Asp 816 to Val
which matches the needs for high-throughput screening
of blood and FFPE samples. In this publication we present
an easy-to-use, unexpensive, and reliable method for
detection of this mutation.
Methods
Samples
The human mast cell line HMC-1 is heterozygous for the
D816V point mutation and was obtained directly from P.
Valent (University of Vienna). HMC-1 was used as a posi-
tive control in all experiments and DNA from tonsil as a
negative control. The presence of Kit mutations was inves-
tigated in archival formalin-fixed, paraffin-embedded tis-
sue (FFPE) from five patients as well as blood samples
from five patients also. All experiments were carried out in
accordance to the Helsinki Declaration.
DNA Extraction
For extraction of total genomic DNA, 20-µm-thick sec-
tions were cut from each paraffin block and DNA was
extracted by standard methods. In brief, dewaxing was
done by xylene and it was followed by overnight protein-
ase K digestion. For genomic DNA preparation the
QIAamp DNA Mini Kit (Cat. No. 51306) was used as well
as for all other DNA preparations (e.g. cell lines and
patient's blood samples). DNA concentration was
obtained by a spectrophotometer (ND-1000, NanoDrop).
Primers and PCR conditions
Following primer combinations have been used for PCR
in combination with the Pure Taq Ready-To-Go PCR
beads system of GE Healthcare (Cat. No. 27-9559-01).
Beads were supplemented with 10 pmol of each primer,
DNA and HPLC grade H2O to a final volume of 25 µl.
Primer combination A (Annealing Temperature 57°C)
MastoMutF1: 5'-TGTGATTTTGGTCTAGCCAGAGTG-3'
MastoMutR1: 5'-TGTTCAGCATACCATGCAAA-3'
Primer combination B (Annealing Temperature 55°C)
MastoMutF2: 5'-TGTGATTTTGGTCTAGCCAGAGTA-3'
MastoMutR1: 5'-TGTTCAGCATACCATGCAAA-3'
Primer combination C (Annealing Temperature 56°C)
MastoMutF3: 5'-TGTGATTTTGGTCTAGCCAGAGTT-3'.
MastoMutR1: 5'-TGTTCAGCATACCATGCAAA-3'
WT sequence KIT: 5'-TGT GAT TTT GGT CTA GCC AGA
GAC-3'
D816V KIT: 5'-TGT GAT TTT GGT CTA GCC AGA GTC-3'
Mutated forward primers have a 3'-terminal mismatch –
G, A or T instead of C – and a second mismatch one base
from the 3'-nucleotide which represents the point muta-
tion A→T.
Each PCR cycle consisted of 30 seconds denaturation at
94°C, 30 seconds annealing at the stated temperatures (A
57°C/B 55°C/C 56°C), and 45 seconds elongation at
72°C and was repeated 36 times. The initial denaturation
was done for four minutes at 94°C and final elongation
for four minutes at 72°C. A 174 bp long fragment was
amplified. Electrophoresis was done on a 2% TAE gel and
the PCR products were cloned by TOPO TA Cloning Kit
(Invitrogen, Part no. 45-0641) and clones were prepared
for sequencing using the GenomeLab Dye Terminator
Cycle Sequencing Kit (Beckman&Coulter, P/N 608120).
Samples were run on the CEQ8800 sequenzer (Beck-
man&Coulter).
Defining sensitivity of PCR-assay (Table 1)
Table 1: 
1. 200 ng gen. DNA HMC-1 (ca. 28571 cells) 0 ng gen. DNA tonsil (ca. 0 cells) no dilution
2. 100 ng gen. DNA HMC-1 (ca. 14285 cells) 100 ng gen. DNA tonsil (ca. 14285 cells) 1:2
3. 50 ng gen. DNA HMC-1 (ca. 7142 cells) 150 ng gen. DNA tonsil (ca. 21428 cells) 1:4
4. 10 ng gen. DNA HMC-1 (ca. 1428 cells) 190 ng gen. DNA tonsil (ca. 27142 cells) 1:20
5. 1 ng gen. DNA HMC-1 (ca. 142 cells) 199 ng gen. DNA tonsil (ca. 28428 cells) 1:200
6. 0,1 ng gen. DNA HMC-1 (ca. 14 cells) 199,9 ng gen. DNA tonsil (ca. 28557 cells) 1:2000
7. 0 ng gen. DNA HMC-1 200 ng DNA tonsil (ca. 28571 cells) no dilutionDiagnostic Pathology 2007, 2:37 http://www.diagnosticpathology.org/content/2/1/37
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200 ng of genomic DNA was the final concentration in
every sensitivity testing.
Results
In an initial experiment the most suitable primer combi-
nation was determined according to Kwok et al. [7] by
testing the three combinations on HMC-1 DNA and tonsil
DNA as a wild-type control. Primer combination A ful-
filled the criteria of specificity in amplifying only the
point mutated allele of HMC-1 (see Fig. 1). B and C
showed amplification of the WT control so that they are
not useful for this assay. The next question which was
addressed was the sensitivity of this PCR based assay. For
this reason a dilution series with HMC-1 DNA and tonsil
DNA had been done whereas the total DNA concentration
of every PCR was 200 ng. The minimum concentration of
HMC-1 DNA which was still detectable was 10 ng in a
total volume of 200 ng of DNA (see Fig. 2). This means a
1:20 dilution. For further testing of primer combination A
on patient's material five blood samples and five FFPE
samples were used as a template for PCR. The clinical
parameters of all these patients clearly indicate mastocyto-
sis and the question was if the Kit point mutation Asp 816
to Val is the reason for this disease pattern. Due to the het-
erogeneity of patient's samples the DNA in every PCR was
variable. At the end the introduced assay with primer
combination (A) is able to detect the point mutation in all
samples of formalin-fixed, paraffin-embedded tissue
(FFPE) and blood (see Fig. 3).
Discussion
Several methods have been implemented before to detect
the point mutation D816V in Kit as a diagnostical proof
for mastocytosis. All of them are highly sensitive PCR-
based methods because of the typically low number of
cells bearing the point mutation. In 1995 Nagata et al. [5]
published a PCR for amplification of introns 16 and 17 of
Kit on DNA and mRNA level of peripheral blood mono-
nuclear cells. The amplicon includes D816V which intro-
duces an A to T substitution at nt 2468 and a new HinfI
restriction site. After digestion of the amplicon and the wt
amplicon the two patterns can be compared. The disad-
vantage of this method is that the transfer from blood
samples to FFPE tissues did not work well because of the
limited quality of DNA (data not shown). Sotlar et al. [8]
published a modified method [9] for mutation detection
in FFPE material by the help of PNA directed PCR clamp-
ing. The PNA suppressed the amplification of the wild-
type target even when the number of tumour cells is very
low in the whole cell fraction. The read-out of this assay
was done in the LightCycler with additional hybridization
probes. Taken all this in account the method needs expen-
sive lab equipment and chemicals. Tan et al. [10] intro-
duced a so-called allele-specific competitive blocker PCR
(ACB-PCR) which needs a modified primer and which
was very similar to the allele-specific PCR of Corless et al.
[11] which also needs a blocking primer. We developed a
simple PCR assay based on the publication of Kwok et al.
[7] and combined it with a Ready-To-Go PCR bead format
(GE Healthcare) which is convenient for high-throughput
screening. The idea of the PCR is that single internal mis-
matches in the oligonucleotides have no significant effect
on PCR product yield. But primer:template mismatches at
the 3'-terminal base reduced the overall PCR product yield
about 100-fold when the mismatch is not involving a T at
the 3' end and when it is coupled with any additional mis-
match 1, 2, or 3 bases upstream from the 3'-nucleotide.
This is why three different forward-primers were designed
for PCR. All these primers have a 3'-prime mismatch com-
pared to the wild-type sequence. This means for
MastoMutF1 G instead of C, MastoMutF2 A instead of C,
and MastoMutF3 T instead of C. At every forward primer
an additional mismatch was introduced one base from
the 3'-nucleotide: the point mutation in Kit. Only the
MastoMutF1 primer showed the expected specificity that
only the point mutated allele of HMC-1 was amplified.
The T mismatch in MastoMutF3 also amplified wild-type
allele from tonsil DNA as well as MastoMutF2. Interest-
Testing of point mutated primers Figure 1
Testing of point mutated primers. 200 ng of genomic HMC1 DNA was used as a PCR template for testing the primer 
combinations. Primer combination A fits the most.Diagnostic Pathology 2007, 2:37 http://www.diagnosticpathology.org/content/2/1/37
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ingly, MastoMutF2 had the lowest signal intensity overall.
For all further experiments the primer combination A
with MastoMutF1 as a forward primer was used. Sensitiv-
ity testing of this assay revealed that 10 ng in a total vol-
ume of 200 ng of DNA could be detected. This means a
1:20 dilution or one mutated cell in a total of 20 cells. It
is known that in human somatic cells the DNA concentra-
tion is around 7 pg per single diploid cell in G0 phase
[12]. 10 ng HMC-1 DNA are around 1428 cells in 27142
tonsil cells (190 ng). Due to the fact that HMC-1 is only
heterozygous for the point mutation the assay decribes a
high sensitivity.
Conclusion
In daily routine the amount of available material as well
as the handling (e.g. fixation) varies. FFPE is the most
widely used material in pathological institutes with conse-
quences for the nucleic acids. During the process of fixa-
tion nucleic acids are cross-linked to proteins which is a
problem for isolation and often degradation occurs before
the material is completely fixed [13]. This is why the
quantity and quality of isolated DNA is not identical and
the amount of template for PCR differs. Taken together,
the introduced assay is able to handle all the differences in
DNA material successfully. In summary, the detection of
Kit point mutation Asp 816 to Val can be done reliably,
sensitively, time-saving, and cost-efficient by the intro-
duced assay.
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Defining sensitivity of PCR assay Figure 2
Defining sensitivity of PCR assay. Total volume of DNA per PCR 200 ng. Lane 1: 200 ng HMC-1 DNA, Lane 2: 100 ng 
HMC-1 DNA + 100 ng tonsil DNA, Lane 3: 50 ng HMC-1 DNA + 150 ng tonsil DNA, Lane 4: 10 ng HMC-1 DNA + 190 ng 
tonsil DNA, Lane 5: 1 ng HMC-1 DNA + 199 ng tonsil DNA, Lane 6: 0,1 ng HMC-1 DNA + 199,9 ng tonsil DNA, Lane 7: 200 
ng tonsil DNA, Lane 8: control.
Detection of point mutation Asp 816 to Val in blood or FFPE samples Figure 3
Detection of point mutation Asp 816 to Val in blood or FFPE samples. Blood FFPE. Lane 1: 35 ng template 25 ng 
template. Lane 2: 190 ng template 20 ng template. Lane 3: 189 ng template 224 ng template. Lane 4: 205 ng template 186 ng 
template. Lane 5: 296 ng template 125 ng template. HMC-1, tonsil (200 ng).Publish with BioMed Central    and   every 
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